Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:33 PM
Ignite Modification Date:
2025-12-24 @ 10:33 PM
NCT ID:
NCT01020435
Eligibility Criteria:
Inclusion Criteria:
* Age \> 21 and \< 75
* Documented Stage I Hypertension
Exclusion Criteria:
* Cardiovascular disorders (Angina pectoris, symptom of CHD; Hemodynamically significant valvular heart disease; Second or Third degree heart block without pacemaker; Stroke, MI, CV surgery within the past 12 months; Claudication, Aortic Coarctation)
* Defibrillator
* Autoimmune Arthropathies
* Pregnancy
* Unwillingness to stop other forms of manual therapy during study
* Unwillingness to sign ICD or preliminary consent
* Intention to move from the area during the next 4 months
* Unwillingness to participate in any of the treatment groups
* Avg SBP\<140 or \>159mm Hg (AND) Avg DBP\<90 or \>99mm Hg
* Any single SBP \> 160mm Hg or DBP\> 100
* BMI \> 40
* Prescription medications with increased risk for CVA
* Current use of anti-coagulant medication/blood thinners
* Active drug or alcohol addiction or abstinent \< 1 year
* Psychiatric diagnosis that would limit patient compliance
* Serious concomitant medical illness
* Contraindication(s) to treatment
* Electrolyte abnormalities seen on lab test
* Renal Failure w/ creatinine \>2.5mg/dL
* Abnormal Liver function tests
* Anemia with hematocrit \< 30%
* Glucose in Urine
* Serum potassium \<3.4 @ baseline
* S/S Renal artery stenosis
* Quebec Task Force Classification 4-9
* Self-reported Arnold Chiari malformation
* Spinal or paraspinal tumors
* Dx with disorder that exhibit spinal joint hypermobility (Marfan Syndrome, Ehlers-Danlos Syndrome, Osteogenesis imperfecta)
* Unstable endocrine disorders
* Osteoporosis
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
21 Years
Maximum Age:
75 Years
Study:
NCT01020435
Study Brief:
Protocol Section:
NCT01020435